Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-06-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularheartadvancedcancerlocally
  Phrases that lowered it: participantsparticipantmgdiseases20
• Sponsor's past termination rate: 21.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Maximum age: 100 (lowers risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 152 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 33.2% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 269 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 10263 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports marked serious: 89.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 25376 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients NCT04581343 · started 2020 · scored riskier than 52% of active trials completed
• Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer NCT04331067 · started 2020 · scored riskier than 85% of active trials terminated
• The Seven Trial: Exploiting the Unfolded Protein Response NCT06076837 · started 2025 · scored riskier than 69% of active trials terminated
• Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients NCT02826486 · started 2016 · scored riskier than 90% of active trials completed
• First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors NCT03681951 · started 2018 · scored riskier than 70% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.